Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKB589 with CAPOX and PD-1 Inhibitors in Advanced Gastric/GEJ Cancer
NCT05632939Phase 2Active, not recruiting
- Sponsor
- AskGene Pharma
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ASKB589 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by AskGene Pharma. Primary endpoints: Number of participants with adverse events as assessed by CTCAE v5.0, Incidence and case number of Dose Limiting Toxicity and 2 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
ASKB589
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05632939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632939.